Similarly, treatment with anti-PD-1/PD-L1 inhibitors did also significantly increase the risk of high-grade pneumonitis (fixed effect, RR: 3.33; 95% CI: 1.68–6.59; p = 0.0006). Here, PDCD1 is linked to pneumonitis.